Key facts
- Elcella’s last known valuation is $5.4M (Feb 2025).
- It has raised $930K; the latest was Angel (individual) ($930K) in Feb 2025.
- Notable investors include Queen Mary Innovation.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Elcella
- ·The full record, as it builds
Funding rounds
No funding rounds for Elcella are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elcella
Producer of patented oral capsules intended to provide a natural alternative to GLP-1 (glucagon-like peptide-1) injections for appetite control and metabolic health. The company offers specially designed and coated capsule technology based on scientific research, enabling individuals seeking non-injectable weight management options to support appetite regulation, reduce blood sugar spikes, and promote gut health.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 10
- Website
- elcella.com/
- Ownership
- Privately Held (backing)
Elcella doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elcella shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elcella in its N-PORT filings yet. We sweep new filings monthly.